What happened to TrkA stock?

Investors are celebrating today’s registration withdrawal with heavy trading of TRKA stock. As of this writing, more than 20 million shares of the company’s stock have changed hands. That’s already above its daily average trading volume of about 18 million shares.

What is trkA (TrkA)?

(TrKA) is a small molecule which inhibits binding of nerve growth factor (NGF) to its primary tyrosine receptor kinase A (TrkA), and is being developed as a treatment for symptoms resulting from osteoarthritis. The Phase IIa program initiated in August 2016 was completed in 2017 and the next steps are under discussion.

Will TrkA stock be diluted without a public offering?

Without a public filing, investors no longer have to worry about TRKA stock being diluted with new outstanding shares. That also means the offering would devalue TRKA shares by being priced below their market value. Both of these typically happen alongside a public offering.

What happened to Troika Media Group?

Troika Media Group, Inc. (Nasdaq: TRKA) ("TMG"), a consumer engagement and customer acquisition group, today announced financial results for the six months ended December 31, 2022, a transition reporting period ("six month transition period") as a result of the Company's change in fiscal year to December 31 from June 30.